Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X by Molecular Oncology
“Primary resistance is to ALK TKIs is a major clinical issue. Nearly 20% of pts in CROWN trial progressed within 6 months! This study in Molecular Oncology shows that MET and NF2 alterations may play a role in primary (early) ALK resistance.”
Authors: Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song